vTv Therapeutics Files 8-K
Ticker: VTVT · Form: 8-K · Filed: Jul 26, 2024 · CIK: 1641489
| Field | Detail |
|---|---|
| Company | Vtv Therapeutics Inc. (VTVT) |
| Form Type | 8-K |
| Filed Date | Jul 26, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, regulatory-update
Related Tickers: VTVT
TL;DR
vTvT filed a routine 8-K, no major news.
AI Summary
On July 26, 2024, vTv Therapeutics Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific new material events, financial figures, or significant transactions were detailed in the provided excerpt.
Why It Matters
This filing indicates vTv Therapeutics is fulfilling its regulatory reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard SEC disclosure and does not appear to contain any new material information that would immediately impact the company's risk profile.
Key Numbers
- 001-37524 — SEC File Number (Identifies the company's filing with the SEC.)
- 47-3916571 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- vTv Therapeutics Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- High Point, NC (location) — Principal executive offices address
FAQ
What is the primary purpose of this 8-K filing?
The filing is primarily for "Other Events" and "Financial Statements and Exhibits," indicating routine regulatory reporting.
When was the earliest event reported in this filing?
The earliest event reported was on July 26, 2024.
What is vTv Therapeutics Inc.'s state of incorporation?
vTv Therapeutics Inc. is incorporated in Delaware.
Where are vTv Therapeutics Inc.'s principal executive offices located?
The principal executive offices are located at 3980 Premier Drive, Suite 310, High Point, NC 27265.
Does this filing announce any new material events or financial results?
Based on the provided excerpt, this filing appears to be a standard disclosure and does not detail any new material events or specific financial results.
Filing Stats: 463 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-07-26 16:17:19
Key Financial Figures
- $0.01 — stered Class A common stock, par value $0.01 per share VTVT NASDAQ Capital Market
Filing Documents
- vtvt-20240726.htm (8-K) — 26KB
- vtvclinicalhold_final.htm (EX-99.1) — 11KB
- 0001641489-24-000057.txt ( ) — 160KB
- vtvt-20240726.xsd (EX-101.SCH) — 2KB
- vtvt-20240726_lab.xml (EX-101.LAB) — 21KB
- vtvt-20240726_pre.xml (EX-101.PRE) — 12KB
- vtvt-20240726_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On July 26, 2024, vTv Therapeutics Inc. (the "Company") issued a press release titled, "vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold". A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 P res s Release dated July 26, 2024 titled "vT v Therapeutics Announces Ca disegliatin Program for Type 1 Diabetes Placed on Clinical Hold" 104 Cover Page Interactive Data File (embedded within Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. VTV THERAPEUTICS INC. By: /s/ Paul J. Sekhri Name: Paul J. Sekhri Title: Chairman, President, and Chief Executive Officer Dated: July 26, 2024